PACAP activates MRGPRX2 on meningeal mast cells to drive migraine-like pain

Migraine ranks among the most prevalent disorders worldwide, leading to disability and decreased quality of life in patients. Recently, neurogenic inflammation has been recognized as a potential underlying pathology contributing to the migraine pain pathway. Mast cells reside in the meninges and hav...

Full description

Saved in:
Bibliographic Details
Published inScientific reports Vol. 13; no. 1; pp. 12302 - 9
Main Authors Sbei, Sami, Moncrief, Taylor, Limjunyawong, Nathachit, Zeng, Yaping, Green, Dustin P.
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 29.07.2023
Nature Publishing Group
Nature Portfolio
Subjects
Online AccessGet full text
ISSN2045-2322
2045-2322
DOI10.1038/s41598-023-39571-y

Cover

More Information
Summary:Migraine ranks among the most prevalent disorders worldwide, leading to disability and decreased quality of life in patients. Recently, neurogenic inflammation has been recognized as a potential underlying pathology contributing to the migraine pain pathway. Mast cells reside in the meninges and have been implicated in contributing to the pathophysiology of migraine. Here we report for the first time that the mouse Mas-Related G-protein-coupled Receptor B2 (MrgprB2), is expressed on meningeal connective tissue mast cells and contributes to Pituitary Adenylate Cyclase Activating Peptide (PACAP)-induced migraine-like pain behavior. We also found that PACAP was able to dose-dependently lead to enzyme release from human mast cells via activation of MRGPRX2; the human homolog of MrgprB2. Using a transgenic MRGPRX2 mouse, we observed significant increases in PACAP-induced migraine-like pain behavior in MRGPRX2 + mice vs mice lacking the receptor. These results reveal both MrgprB2 and MRGPRX2 as important contributors to neuropeptide-induced migraine pain.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-023-39571-y